66 related articles for article (PubMed ID: 27687663)
1. [Expression of CDK6 in early ovarian cancer and its clinical significance].
Ling C; Liu S; Wang Y; Zhang FC; Du Y
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(9):1271-1275. PubMed ID: 27687663
[TBL] [Abstract][Full Text] [Related]
2. [Expression of CDK6 in nasopharyngeal carcinoma and its clinical significance].
Luo X; Qin J; Huang Y; Liu J; Wang Y; Wang H; Chen J
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1811-4. PubMed ID: 24369251
[TBL] [Abstract][Full Text] [Related]
3. [Expression of CDK6 and FOXM1 in peripheral T-cell lymphoma and their significance].
Feng HN; Shao XX; Bu P; Zhang F; Wang YJ; Xi YF; Guo WN
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):594-600. PubMed ID: 32486537
[No Abstract] [Full Text] [Related]
4. [Correlation between eIF3a and HE4 expression and ovarian cancer].
Wang J; Luo C; Wang Y; Tang Y; Fang K; Zeng L; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Dec; 39(12):1240-5. PubMed ID: 25544161
[TBL] [Abstract][Full Text] [Related]
5. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
Arsenic R; Braicu EI; Letsch A; Dietel M; Sehouli J; Keilholz U; Ochsenreither S
BMC Cancer; 2015 Oct; 15():784. PubMed ID: 26499264
[TBL] [Abstract][Full Text] [Related]
7. Expression of CDK6 in Oral Squamous Cell Carcinomas.
Andisheh-Tadbir A; Ashraf MJ; Jeiroodi N
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1013-1016. PubMed ID: 29693970
[TBL] [Abstract][Full Text] [Related]
8. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
9. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
10. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Mendrzyk F; Radlwimmer B; Joos S; Kokocinski F; Benner A; Stange DE; Neben K; Fiegler H; Carter NP; Reifenberger G; Korshunov A; Lichter P
J Clin Oncol; 2005 Dec; 23(34):8853-62. PubMed ID: 16314645
[TBL] [Abstract][Full Text] [Related]
11. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
12. Expression of cdk6 in head and neck squamous cell carcinoma.
Poomsawat S; Sanguansin S; Punyasingh J; Vejchapipat P; Punyarit P
Clin Oral Investig; 2016 Jan; 20(1):57-63. PubMed ID: 25929813
[TBL] [Abstract][Full Text] [Related]
13. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
Huang S; Qing C; Huang Z; Zhu Y
Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
[TBL] [Abstract][Full Text] [Related]
14. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
16. High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer.
Liu Z; Yamanouchi K; Ohtao T; Matsumura S; Seino M; Shridhar V; Takahashi T; Takahashi K; Kurachi H
Anticancer Res; 2014 May; 34(5):2331-40. PubMed ID: 24778040
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
18. PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.
Wang L; Niu CH; Wu S; Wu HM; Ouyang F; He M; He SY
Oncol Rep; 2016 Jan; 35(1):488-96. PubMed ID: 26549570
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.
Abdel Azim S; Duggan-Peer M; Sprung S; Reimer D; Fiegl H; Soleiman A; Marth C; Zeimet AG
Oncotarget; 2016 Jun; 7(24):37205-37214. PubMed ID: 27174921
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
